Immunotherapy for Peritoneal Metastases from Gastric Cancer: Rationale, Current Practice and Ongoing Trials

Round 1

Reviewer 1 Report

In their manuscript, the authors clearly describe the rationale, current practice and ongoing studies on immunotherapy of peritoneal metastases in gastric cancer. The work deals with a very relevant topic, since peritoneal metastases lead to the high lethality of gastric cancer and there is still no significant improvement in their treatment.
The end of the manuscript is not very well done because it ends rather abruptly. There is a brief summary missing. What is the conclusion of the paper?

minor comments: 
p.3 from line 116, tumor mutational burden should be included as a possible selection factor for response to immunotherapy.
p. 2, line 55: reference 4 does not seem to be in the right place
p.4 line 173 immune instead of inmune
Table 1: The headings of the first two columns are not correct.

Author Response

Thank you very much for the comments, please see the attachment.

Reviewer 2 Report

This review article described peritoneal metastases from gastric cancer and its immunotherapy. Immunotherapy is required for clinical better outcomes in gastric cancer. Recurrence in GC patients occurs most frequently in the form of peritoneal metastasis. I consider that immunotherapy is one of important strategy for gastric cancer treatment. The contents in this article are helpful for understanding gastric cancer immunotherapy.

Comments:

Table 1 showed summary of clinical trials with immunotherapy in GC. I feel this table is busy. Please revise a table to be easy for reader. I think clear placement and sentence are helpful to understand the content for reader.

Author Response

thank you very much, please see the attachment